我们在淋巴细胞性疾病患儿中进行天冬酰胺酶活性测定的经验。
Our Experiences with Asparaginase Activity Measurements in Children with Lymphoblastic Diseases.
作者信息
Müller Judit, Egyed Petra, Erdelyi Daniel, Kovacs Krisztian, Mudra Katalin, Szabo Sandor, Egyed Balint, Gabor Kovacs
机构信息
2nd Department of Pediatrics, Semmelweis University, 1094 Budapest, Hungary.
County Hospital Fejer, Szent Gyorgy Hospital, 8000 Szekesfehervar, Hungary.
出版信息
Children (Basel). 2023 Jul 2;10(7):1160. doi: 10.3390/children10071160.
BACKGROUND
Asparaginase is a key component of chemotherapy protocols for the treatment of lymphoblastic malignancies among children. Adequate asparagine depletion is an important factor to achieve optimal therapeutic outcomes.
METHODS
Over a 3.5 year period, 106 patients were monitored for asparaginase activity (329 samples) in a single center of the Hungarian Pediatric Oncology-Hematology Group. In Hungary, three asparaginase products are available: native E. coli ASNase (Kidrolase), a pegylated form of this enzyme (Pegaspargase) and another native product from Erwinia chrysanthemi (Erwinase). A retrospective data analysis was performed.
RESULTS
In 81% (268/329) of our patients, AEA levels were in the optimal therapeutic range of over 100 IU/L. Of 106 patients, 13 (12%) were diagnosed with 'silent inactivation'.
CONCLUSIONS
Monitoring of AEA can help to identify patients with 'silent inactivation' and their asparaginase therapy can thus be optimized.
背景
天冬酰胺酶是儿童淋巴细胞恶性肿瘤化疗方案的关键组成部分。充分的天冬酰胺消耗是实现最佳治疗效果的重要因素。
方法
在3.5年的时间里，匈牙利儿科肿瘤血液学组的一个中心对106例患者的天冬酰胺酶活性进行了监测（共329份样本）。在匈牙利，有三种天冬酰胺酶产品可供使用：天然大肠杆菌天冬酰胺酶（Kidrolase）、该酶的聚乙二醇化形式（培门冬酶）以及来自菊欧文氏菌的另一种天然产品（Erwinase）。进行了回顾性数据分析。
结果
在我们81%（268/329）的患者中，天冬酰胺酶活性（AEA）水平处于超过100 IU/L的最佳治疗范围内。在106例患者中，13例（12%）被诊断为“沉默失活”。
结论
监测AEA有助于识别“沉默失活”的患者，从而优化他们的天冬酰胺酶治疗。
Zotero 插件